Abstract
The taxanes (paclitaxel and docetaxel) currently play an important role in the managment of cancers of the ovary, uterus and cervix. In each of these gynecologic malignancies, the drugs are routinely employed in combination with a platinum agent, although when delivered as single agents they may provide substantial palliative benefit. It is important to recognize that despite the documented major utility of this class of agents in the treatment of gynecologic cancers, many highly relevant questions remain, including determining optimal drug delivery schedules, the duration of treatment and the role of regional paclitaxel administration.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.